Tumor-associated antigen presentation via major histocompatibility complex class I and II molecules on dendritic cells (null)

Tumor-associated antigen presentation via major histocompatibility complex class I and II molecules on dendritic cells describes the essential immune process in which dendritic cells acquire tumor-derived antigens and display them to T cells using MHC molecules. MHC class I molecules present intracellular tumor antigens to CD8^+^ cytotoxic T cells (critical for tumor cell killing), while MHC class II molecules present extracellular or endocytosed antigens to CD4^+^ T helper cells (important for orchestrating broader immune responses)[1][2][3][4][5]. Cross-presentation refers to DCs' ability to present exogenous antigens via MHC-I, crucial for recognizing tumors and viruses. This process is frequently impaired in the tumor microenvironment, limiting immunotherapy efficacy[5][7][9]. Therapeutic strategies aim to enhance this presentation—including DC vaccines and checkpoint blockade—highlighting the pathway's central role in cancer immunotherapy.

Other names

MHC-I antigen presentation on dendritic cellsMHC-II antigen presentation on dendritic cellsDendritic cell antigen presentationTumor antigen cross-presentation

Enhanced antigen loading (DC vaccines, adjuvants) Augmented T cell response through increased antigen presentation[4][5] Modulation of tumor microenvironment to restore DC function